Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

Selank

Cat 2 → Pending Cat 1

Neuropeptide · Research peptide (approved in Russia)

Synthetic analog of tuftsin researched for anxiolytic and immunomodulatory effects. Approved in Russia; not FDA-approved in the US.

About

Mechanism

Synthetic analog of the immunomodulatory peptide tuftsin with a stabilizing Pro-Gly-Pro sequence. Modulates GABA-A receptor expression, enhances enkephalin levels, and provides anxiolytic effects without sedation or dependence.

Half-Life

Approximately 3-5 minutes (intranasal delivery extends effective duration)

Route

subcutaneous

Frequency

Once daily (intranasal or SC)

Clinical Dosing

200-400 mcgonce daily (intranasal or sc)

Not FDA-approved. Approved in Russia for anxiety and cognitive function. Currently FDA Category 2 (restricted) in US. Pending return to Category 1.

Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.

Regulatory Status

FDA Category

Research peptide in US (approved in Russia)

Reclassification

pending

Date Restricted

2023-09-29

Announced Return

2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Protocol

Source: Zozulya et al., Zh Nevrol Psikhiatr Im S S Korsakova, 2008 (PMID 18454096)

Dose	Duration	Draw (3 mg vial in 2mL)	Notes
300 mcg	Maintenance	0.20 mL (20 units)	Standard research dose

Available Vial Sizes

3 mg

3 mg vial

5 mg

5 mg vial

Citations

[1]Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova, 108(4), 38-48 (Russian) — PMID 18454096. Link(Reviewed: 2026-04-16)